Schedule
14C Information
Information Statement Pursuant to Section
14(c) of
the Securities Exchange Act of 1934
Check the appropriate box:
[X] Preliminary
Information Statement
[ ] Confidential,
for Use of the Commission Only (as permitted by Rule 14c-5(d)(2))
[ ] Definitive
Information Statement
GALA
GLOBAL INC.
(Name of Registrant As Specified In Its
Charter)
Payment of Filing Fee (Check the
appropriate box):
[X] No fee
required
[ ] Fee
computed on table below per Exchange Act Rules 14c-5(g) and 0-11
(1) Title of each class of securities
to which transaction applies:
(2) Aggregate number of securities
to which transaction applies:
(3) Per unit price or other underlying value of transaction
computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate
value of transaction:
(5) Total fee paid:
[ ] Fee
paid previously with preliminary materials.
[ ] Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule
and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration
Statement No.:
(3) Filing Party:
(4) Date Filed:
SCHEDULE 14C INFORMATION
THIS INFORMATION STATEMENT IS BEING PROVIDED
TO
YOU BY THE BOARD OF DIRECTORS OF GALA GLOBAL
INC.
WE ARE NOT ASKING YOU FOR A PROXY AND YOU
ARE
REQUESTED NOT TO SEND US A PROXY
SCHEDULE 14C INFORMATION STATEMENT
Pursuant to Regulation 14C of the Securities Exchange Act of 1934 as amended
Gala Global Inc.
2780 South Jones Blvd. #3725
Las Vegas, Nevada 89146
December 26, 2017
NOTICE OF STOCKHOLDER ACTION BY WRITTEN
CONSENT
GENERAL INFORMATION
This
Information Statement (the "Information Statement") has been filed with the Securities and Exchange Commission and is
being furnished, pursuant to Section 14C of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to
the holders (the "Stockholders") of the common stock, par value $.001 per share (the "Common Stock"), of Gala
Global Inc., a Nevada Corporation (the "Company"), to notify such Stockholders that on or about November 30, 2017, the
Company received a majority written consent in lieu of a meeting of Stockholders from holders of the Company in accordance with
Nevada Corporate Law. The holders authorized the following:
|
·
|
to change the name of the Company to "Gala Pharmaceutical Inc." (the "Name Change").
|
On
November 30, 2017, the Board of Directors of the Company approved the Name Change, subject to Stockholder approval.
On
November 30, 2017, the Majority Stockholders approved the Name Change by written consent in lieu of a meeting in accordance with
the Nevada Revises Statutes. Accordingly, your consent is not required and is not being solicited in connection with the approval
of the Name Change (“Current Action”).
WE
ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND A PROXY.
Date: December 26, 2017
|
For the Board of Directors of
|
|
|
|
GALA GLOBAL INC.
|
|
|
|
By:
/s/ Maqsood Rehman
|
|
Maqsood Rehman, CEO, President
|
|
|
RECOMMENDATION OF THE BOARD OF DIRECTORS
The Board believes that the Current Action
is in the best interest of the Company and the Stockholders as the Name Change will better reflect the nature of the Company's
new business direction.
The Board approved the Current action on
November 30, 2017 and the Majority Stockholders approved the action on November 30, 2017 as well.
ACTIONS TO BE TAKEN
This Information Statement contains a brief
summary of the current of the material aspects of the actions approved by Board and the Majority Stockholders.
AMENDMENT OF ARTICLES OF INCORPORATION
The Board of Directors has
determined that the Company intends to provide agricultural and pharmaceutical customers with plant genomic research, genomic breeding,
specialty genomic products and laboratory services. This strategy will align Gala Global Inc. with the biopharmaceutical and pharmaceutical
services markets. The Company’s business strategy entails the use of proprietary equipment and techniques to ensure the genetic
fingerprint of each plant is identical and is cultivated in a controlled environment, significantly reducing the variability of
each plants yield. The Company will provide cGMP (Good Manufacturing Practices) production of Active Pharmaceutical Ingredients
(API) for use in clinical trials required to make effectiveness claims for varying medical conditions. The Name Change to Gala
Pharmaceutical Inc. better reflects the nature of the Company's new business direction.
On
November 30, 2017, the Company's Board of Directors and the Majority Stockholders owning a majority of the Company's voting securities
approved a resolution authorizing the Company to amend the Articles of Incorporation to change the Company's name to Gala Pharmaceutical
Inc. The Board believes that the Name Change better reflects the nature of the Company's anticipated operations.
The
Company's filed Certificate of Amendment to the Articles of Incorporation filed with the State of Nevada reflecting the name change
on December 5, 2017 and is attached to this Information statement as Exhibit A. The effectiveness of the name change will be and
on the date that is twenty (20) days following the filing and mailing of the Definitive Information Statement to Stockholders of
Record
ADDITIONAL INFORMATION
The
Company is subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and in accordance therewith files reports, proxy statements and other information including annual and quarterly reports on Form
10-K and 10-Q (the "1934 Act Filings") with the Securities and Exchange Commission (the "Commission"). Reports
and other information filed by the Company can be inspected and copied at the public reference facilities maintained at the Commission
at Room 1024, 450 Fifth Street, NM., Washington, DC 20549, Copies of such material can be obtained upon written request addressed
to the Commission, Public Reference Section, 450 Fifth Street, N.W., Washington, D.C. 20549, at prescribed rates. The Commission
maintains a web site on the Internet (
http://www.sec.gov
) that contains reports, proxy and information
statements and other information regarding issuers that file electronically with the Commission through the Electronic Data Gathering,
Analysis and Retrieval System ("EDGAR").
The
following documents as filed with the Commission by the Company are incorporated herein by reference:
1.
|
|
Annual Report on Form 10-K and Form 10-K/A for the year ended November 30, 2016; and
|
2.
|
|
Quarterly Reports on Form 10-Q for the quarters ended February 28, 2017, May 31, 2017
and August 31, 2017.
|
The
Company shall provide, without charge, to each person to whom an Information Statement is delivered, upon written or oral request
of such person and by first class mail or other equally prompt means within one (1) business day of receipt of such request, a
copy of any and all of the information that has been incorporated by reference in the Information Statement (not including exhibits
to the information that is incorporated by reference unless such exhibits are specifically incorporated by reference into the information
that the Information Statement incorporates), and the address and telephone numbers to which such a request is to be directed.
OUTSTANDING VOTING SECURITIES
As
of the day of the consent by the Majority stockholders, November 30, 2017, our authorized capital stock consists of 500,000,000
shares of Common Stock, par value $0.001 per share, of which 42,201,590 shares were outstanding and 10,000,000 shares of preferred
stock with a par value of $0.001 per share of which 500,000 shares were issued and outstanding. Each preferred share has voting
rights equivalent to 500 shares of common stock.
On
November 30, 2017, the holders of the 500,000 preferred shares (equivalent to 250,000,000 voting common shares, or approximately
85.6% of the then outstanding plus the voting preferred) executed and delivered to the Company a written consent approving the
Current Action. As the Current Action was approved by the Majority Stockholders, consisting of James Haas (also voting the Greengro
Technologies, Inc. preferred shares),166,667,000 shares, and Owen Naccarato, 83,333,000 shares, no proxies are being solicited
with this Information Statement.
The
Nevada Revised Statutes provides that unless the Company’s Articles provides otherwise, Stockholders may take action without
a meeting of stockholders and without prior notice if a consent in writing, setting forth the action so taken, is signed by the
Stockholders having not less than the minimum number of votes that would be necessary to take such action at a meeting at which
all shares entitled to vote thereon were present.
SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT
The
following information table sets forth certain information regarding the Company's common stock owned on November 30, 2017 by (i)
each who is known by the Company to own beneficially more than 5% of its outstanding Common Stock, (ii) each director and officer,
and (iii) all officers and directors as a group:
|
|
|
|
Common Stock
|
|
Series A Preferred
|
|
|
|
|
Number of
|
|
|
|
Number of
|
|
|
|
|
|
|
Shares
|
|
|
|
shares
|
|
|
|
|
|
|
Beneficially
|
|
Percentage
|
|
Beneficially
|
|
Percentage
|
Name of Beneficially Owned
|
|
Owned
|
|
of Class
|
|
Owned
|
|
of Class
|
James Haas (1)
|
|
|
|
|
|
|
|
|
|
15406 Escalona Road
|
|
|
|
|
|
|
|
|
|
La Mirada, CA 90638
|
|
|
10,000,000
|
|
23.60%
|
|
333,334
|
|
66.70%
|
|
|
|
|
|
|
|
|
|
|
|
Timothy J. Madden
|
|
|
|
|
|
|
|
|
|
2022 21st Street
|
|
|
|
|
|
|
|
|
|
Cuyahoga Falls, OH 44223
|
|
6,433,333
|
|
15.20%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Romina Martinez
|
|
|
|
|
|
|
|
|
|
4860 Casa Bonita CT.
|
|
|
|
|
|
|
|
|
|
Bonita, CA 91902
|
|
|
1,500,000
|
|
3.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Owen Naccarato
|
|
|
|
|
|
|
|
|
|
77 Eaglecreek
|
|
|
|
|
|
|
|
|
|
Irvine, CA 92618
|
|
|
10,352,131
|
|
24.40%
|
|
166,666
|
|
33.30%
|
|
|
|
|
|
|
|
|
|
|
|
Maqsood Rehman
|
|
|
|
|
|
|
|
|
|
2134 Deer Springs Lane
|
|
|
|
|
|
|
|
|
|
Brea, CA 92821
|
|
1,500,000
|
|
3.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allison Hess
|
|
|
|
|
|
|
|
|
|
402 W. Broadway, 25th Floor
|
|
|
|
|
|
|
|
|
San Diego, CA 92201
|
|
|
1,525,000
|
|
3.60%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Directors and Officers as a Group
|
4,525,000
|
|
10.60%
|
|
|
|
|
(1)
|
|
James Haas's beneficially owned preferred shares includes
the 75,000 preferred shares owed by Greengro Technologies, Inc. Mr. Haas was granted Greengro's voting rights for purposes of
this Company Action. Mr. Haas beneficially owns the Haas, Inc. common shares as well.
|
DISSENTER'S RIGHTS OF APPRAISAL
The
Stockholders have no right under Nevada Corporate Law, the Company's Articles of Incorporation consistent with above, or ByLaws
to dissent from any of the provisions adopted in the Amendment.
EFFECTIVE DATE OF NAME CURRENT ACTION
Pursuant
to Rule 14c-2 under the Exchange Act, the Current Action shall not be affective until a date at least twenty (20) days after the
date on which the Definitive Information Statement has been mailed to the Stockholders.
MISCELLANEOUS MATTERS
As a matter of regulatory compliance, we
are sending you this Information Statement which describes the purpose and effect of the above action. Your consent to the above
action is not required and is not being solicited in connection with this action.
The Board of Directors has fixed the close
of business on November 30, 2017, as the record date (the “Record Date”) for the determination os Stockholders who
are entitled to receive this information Statement.
This Information Statement is being provided
to you pursuant to Section 14C of the Exchange Act and Regulation 14C and Schedule 14C thereunder.
Pursuant to
the requirements of the Securities Exchange Act of 1934, Gala Global Inc. has duly caused this report to be signed by the undersigned
hereunto authorized.
Gala Global Inc.
By:
/s/ Maqsood Rehman
Maqsood Rehman
Exhibit A
BARBARA K. CEGAVSKE
Secretary of State
202 North Carson Street
Carson City, Nevada 89701-4201
(775) 684-5708
Website: www.nvsos.gov
Certificate of Amendment
(PURSUANT TO NRS 78.385 AND 78.390)
USE
BLACK INK ONLY - DO NOT HIGHLIGHT
|
ABOVE SPACE IS FOR OFFICE USE ONLY
|
Certificate of
Amendment to Articles of Incorporation
For Nevada Profit
Corporations
(Pursuant to NRS 78.385
and 78.390 - After Issuance of Stock)
Gala Global Inc.
Article I has been changed. The new
name of the corporation is:
Gala Pharmaceutical, Inc.
1. Name of corporation:
2.
The articles have been amended as follows: (provide article numbers, if available)
3. The vote by which
the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such
greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by
the provisions of the articles of incorporation* have voted in favor of the amendment is:
4.
Effective date and time of filing: (optional) Date: Time:
(must not be later than 90 days after the
certificate is filed)
5. Signature: (required)
X
Maqsood
Rehman